Cerus (NASDAQ:CERS - Get Free Report)'s stock had its "overweight" rating restated by Cantor Fitzgerald in a note issued to investors on Friday,Benzinga reports. They currently have a $4.00 price objective on the biotechnology company's stock. Cantor Fitzgerald's target price would indicate a potential upside of 145.40% from the stock's previous close.
Cerus Price Performance
Shares of NASDAQ:CERS traded down $0.01 during midday trading on Friday, reaching $1.63. 1,301,914 shares of the company's stock traded hands, compared to its average volume of 1,512,589. The company has a market cap of $302.71 million, a P/E ratio of -14.82 and a beta of 1.29. The company has a fifty day simple moving average of $1.74 and a two-hundred day simple moving average of $1.83. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59. Cerus has a 1 year low of $1.38 and a 1 year high of $2.59.
Cerus (NASDAQ:CERS - Get Free Report) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). The business had revenue of $50.81 million for the quarter, compared to analyst estimates of $50.81 million. Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. Equities analysts predict that Cerus will post -0.08 EPS for the current fiscal year.
Insider Buying and Selling at Cerus
In related news, Director Eric Bjerkholt sold 20,000 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $1.78, for a total transaction of $35,600.00. Following the completion of the sale, the director now directly owns 162,133 shares in the company, valued at approximately $288,596.74. The trade was a 10.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.40% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rockport Wealth LLC acquired a new stake in shares of Cerus in the fourth quarter valued at about $25,000. Cibc World Markets Corp purchased a new stake in Cerus during the 4th quarter valued at about $26,000. R Squared Ltd purchased a new stake in Cerus during the 4th quarter valued at about $29,000. Virtu Financial LLC acquired a new stake in Cerus in the 4th quarter valued at about $33,000. Finally, Dark Forest Capital Management LP purchased a new position in Cerus in the 4th quarter worth approximately $34,000. Hedge funds and other institutional investors own 78.37% of the company's stock.
About Cerus
(
Get Free Report)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
See Also
Before you consider Cerus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cerus wasn't on the list.
While Cerus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
